Gender-Related Impact of Sclerostin Antibody on Bone in the Osteogenesis Imperfecta Mouse

Osteogenesis imperfecta (OI), which is most often due to a collagen type 1 gene mutation, is characterized by low bone density and bone fragility. In OI patients, gender-related differences were reported, but data in the literature are not convergent. We previously observed that sclerostin antibody...

Full description

Bibliographic Details
Main Authors: Mickaël Cardinal, Antoine Chretien, Thomas Roels, Sébastien Lafont, Michael S. Ominsky, Jean-Pierre Devogelaer, Daniel H. Manicourt, Catherine Behets
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Genetics
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fgene.2021.705505/full
id doaj-17cd81ff7d3843b595ac6ab978454a8f
record_format Article
spelling doaj-17cd81ff7d3843b595ac6ab978454a8f2021-08-10T07:43:12ZengFrontiers Media S.A.Frontiers in Genetics1664-80212021-08-011210.3389/fgene.2021.705505705505Gender-Related Impact of Sclerostin Antibody on Bone in the Osteogenesis Imperfecta MouseMickaël Cardinal0Antoine Chretien1Thomas Roels2Sébastien Lafont3Michael S. Ominsky4Michael S. Ominsky5Jean-Pierre Devogelaer6Daniel H. Manicourt7Catherine Behets8Pole of Morphology, Institut de Recherche Expérimentale et Clinique, UCLouvain, Brussels, BelgiumPole of Morphology, Institut de Recherche Expérimentale et Clinique, UCLouvain, Brussels, BelgiumPole of Morphology, Institut de Recherche Expérimentale et Clinique, UCLouvain, Brussels, BelgiumPole of Morphology, Institut de Recherche Expérimentale et Clinique, UCLouvain, Brussels, BelgiumRadius Inc., Waltham, MA, United StatesAmgen Inc., Thousand Oaks, CA, United StatesPole of Rheumatic Pathologies, Institut de Recherche Expérimentale et Clinique, UCLouvain, Brussels, BelgiumPole of Rheumatic Pathologies, Institut de Recherche Expérimentale et Clinique, UCLouvain, Brussels, BelgiumPole of Morphology, Institut de Recherche Expérimentale et Clinique, UCLouvain, Brussels, BelgiumOsteogenesis imperfecta (OI), which is most often due to a collagen type 1 gene mutation, is characterized by low bone density and bone fragility. In OI patients, gender-related differences were reported, but data in the literature are not convergent. We previously observed that sclerostin antibody (Scl-Ab), which stimulates osteoblast Wnt pathway via sclerostin inactivation, improved spine and long-bone parameters and biomechanical strength in female oim/oim mice, a validated model of human type 3 OI. Here, we wanted to highlight the effect of Scl-Ab on male oim/oim bones in order to identify a possible distinct therapeutic effect from that observed in females. According to the same protocol as our previous study with female mice, male wild-type (Wt) and oim/oim mice received vehicle or Scl-Ab from 5 to 14 weeks of age. Clinimetric and quantitative bone parameters were studied using X-rays, peripheral quantitative computed tomography, microradiography, and dynamic histomorphometry and compared to those of females. Contrary to Wt mice, male oim/oim had significantly lower weight, snout–sacrum length, and bone mineral content than females at 5 weeks. No significant difference in these clinimetric parameters was observed at 14 weeks, whereas male oim showed significantly more long-bone fractures than females. Scl-Ab improved bone mineral density and bone volume/total volume ratio (BV/TV) of vertebral body in Wt and oim/oim, without significant difference between male and female at 14 weeks. Male vehicle oim/oim had a significantly lower cortical thickness (Ct.Th) and BV/TV of tibial diaphysis than female and showed a higher number of fractures at 14 weeks. Scl-Ab increased midshaft periosteal apposition rate in such a way that tibial Ct.Th of male oim/oim was not significantly different from the female one at 14 weeks. The number of fractures was lower in male than female oim/oim after 14 weeks of Scl-Ab treatment, but this difference was not significant. Nevertheless, Scl-Ab–treated oim/oim male and female mice remained smaller than the Wt ones. In conclusion, our results highlighted differences between male and female oim/oim at 4 and 14 weeks of age, as well as some male-specific response of cortical bone to Scl-Ab. These gender-related particularities of oim/oim should be considered when testing experimental treatments.https://www.frontiersin.org/articles/10.3389/fgene.2021.705505/fullosteogenesis imperfectaoim/oimsclerostin antibodyfracturebone qualitybiomechanical strength
collection DOAJ
language English
format Article
sources DOAJ
author Mickaël Cardinal
Antoine Chretien
Thomas Roels
Sébastien Lafont
Michael S. Ominsky
Michael S. Ominsky
Jean-Pierre Devogelaer
Daniel H. Manicourt
Catherine Behets
spellingShingle Mickaël Cardinal
Antoine Chretien
Thomas Roels
Sébastien Lafont
Michael S. Ominsky
Michael S. Ominsky
Jean-Pierre Devogelaer
Daniel H. Manicourt
Catherine Behets
Gender-Related Impact of Sclerostin Antibody on Bone in the Osteogenesis Imperfecta Mouse
Frontiers in Genetics
osteogenesis imperfecta
oim/oim
sclerostin antibody
fracture
bone quality
biomechanical strength
author_facet Mickaël Cardinal
Antoine Chretien
Thomas Roels
Sébastien Lafont
Michael S. Ominsky
Michael S. Ominsky
Jean-Pierre Devogelaer
Daniel H. Manicourt
Catherine Behets
author_sort Mickaël Cardinal
title Gender-Related Impact of Sclerostin Antibody on Bone in the Osteogenesis Imperfecta Mouse
title_short Gender-Related Impact of Sclerostin Antibody on Bone in the Osteogenesis Imperfecta Mouse
title_full Gender-Related Impact of Sclerostin Antibody on Bone in the Osteogenesis Imperfecta Mouse
title_fullStr Gender-Related Impact of Sclerostin Antibody on Bone in the Osteogenesis Imperfecta Mouse
title_full_unstemmed Gender-Related Impact of Sclerostin Antibody on Bone in the Osteogenesis Imperfecta Mouse
title_sort gender-related impact of sclerostin antibody on bone in the osteogenesis imperfecta mouse
publisher Frontiers Media S.A.
series Frontiers in Genetics
issn 1664-8021
publishDate 2021-08-01
description Osteogenesis imperfecta (OI), which is most often due to a collagen type 1 gene mutation, is characterized by low bone density and bone fragility. In OI patients, gender-related differences were reported, but data in the literature are not convergent. We previously observed that sclerostin antibody (Scl-Ab), which stimulates osteoblast Wnt pathway via sclerostin inactivation, improved spine and long-bone parameters and biomechanical strength in female oim/oim mice, a validated model of human type 3 OI. Here, we wanted to highlight the effect of Scl-Ab on male oim/oim bones in order to identify a possible distinct therapeutic effect from that observed in females. According to the same protocol as our previous study with female mice, male wild-type (Wt) and oim/oim mice received vehicle or Scl-Ab from 5 to 14 weeks of age. Clinimetric and quantitative bone parameters were studied using X-rays, peripheral quantitative computed tomography, microradiography, and dynamic histomorphometry and compared to those of females. Contrary to Wt mice, male oim/oim had significantly lower weight, snout–sacrum length, and bone mineral content than females at 5 weeks. No significant difference in these clinimetric parameters was observed at 14 weeks, whereas male oim showed significantly more long-bone fractures than females. Scl-Ab improved bone mineral density and bone volume/total volume ratio (BV/TV) of vertebral body in Wt and oim/oim, without significant difference between male and female at 14 weeks. Male vehicle oim/oim had a significantly lower cortical thickness (Ct.Th) and BV/TV of tibial diaphysis than female and showed a higher number of fractures at 14 weeks. Scl-Ab increased midshaft periosteal apposition rate in such a way that tibial Ct.Th of male oim/oim was not significantly different from the female one at 14 weeks. The number of fractures was lower in male than female oim/oim after 14 weeks of Scl-Ab treatment, but this difference was not significant. Nevertheless, Scl-Ab–treated oim/oim male and female mice remained smaller than the Wt ones. In conclusion, our results highlighted differences between male and female oim/oim at 4 and 14 weeks of age, as well as some male-specific response of cortical bone to Scl-Ab. These gender-related particularities of oim/oim should be considered when testing experimental treatments.
topic osteogenesis imperfecta
oim/oim
sclerostin antibody
fracture
bone quality
biomechanical strength
url https://www.frontiersin.org/articles/10.3389/fgene.2021.705505/full
work_keys_str_mv AT mickaelcardinal genderrelatedimpactofsclerostinantibodyonboneintheosteogenesisimperfectamouse
AT antoinechretien genderrelatedimpactofsclerostinantibodyonboneintheosteogenesisimperfectamouse
AT thomasroels genderrelatedimpactofsclerostinantibodyonboneintheosteogenesisimperfectamouse
AT sebastienlafont genderrelatedimpactofsclerostinantibodyonboneintheosteogenesisimperfectamouse
AT michaelsominsky genderrelatedimpactofsclerostinantibodyonboneintheosteogenesisimperfectamouse
AT michaelsominsky genderrelatedimpactofsclerostinantibodyonboneintheosteogenesisimperfectamouse
AT jeanpierredevogelaer genderrelatedimpactofsclerostinantibodyonboneintheosteogenesisimperfectamouse
AT danielhmanicourt genderrelatedimpactofsclerostinantibodyonboneintheosteogenesisimperfectamouse
AT catherinebehets genderrelatedimpactofsclerostinantibodyonboneintheosteogenesisimperfectamouse
_version_ 1721212434573688832